Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Amortization (2016 - 2025)

Historic Amortization for Ascendis Pharma A (ASND) over the last 14 years, with Q4 2025 value amounting to $1.3 billion.

  • Ascendis Pharma A's Amortization rose 1388.4% to $1.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 billion, marking a year-over-year increase of 1388.4%. This contributed to the annual value of $1.3 billion for FY2025, which is 1055.33% up from last year.
  • Per Ascendis Pharma A's latest filing, its Amortization stood at $1.3 billion for Q4 2025, which was up 1388.4% from $1.2 billion recorded in Q3 2025.
  • In the past 5 years, Ascendis Pharma A's Amortization ranged from a high of $1.3 billion in Q4 2025 and a low of $179.3 million during Q4 2022
  • For the 5-year period, Ascendis Pharma A's Amortization averaged around $926.6 million, with its median value being $968.8 million (2025).
  • As far as peak fluctuations go, Ascendis Pharma A's Amortization soared by 258474.83% in 2021, and later plummeted by 3781.41% in 2023.
  • Ascendis Pharma A's Amortization (Quarter) stood at $183.0 million in 2021, then decreased by 2.02% to $179.3 million in 2022, then surged by 341.96% to $792.4 million in 2023, then skyrocketed by 43.06% to $1.1 billion in 2024, then increased by 13.88% to $1.3 billion in 2025.
  • Its Amortization stands at $1.3 billion for Q4 2025, versus $1.2 billion for Q3 2025 and $1.1 billion for Q2 2025.